Argenx rijft vlotjes 100 miljoen dollar binnen bij beursgang op Nasdaq

19
/05

De interesse in Argenx op Nasdaq was dermate groot dat het bedrijf 100 miljoen dollar (90 miljoen euro) bij elkaar sprokkelde. Argenx maakt geneesmiddelen op basis van kameelachtigen zoals lama's. Het probeert de kenmerken van die antilichamen in te brengen in menselijke antistoffen. De technologie dient voor de behandeling van auto-immuunziektes en meerdere kankervormen.

Persbericht Argenx

Published: 03:57 CEST 18-05-2017 /GlobeNewswire /Source: argenx N.V. / : ARGX /ISIN: NL0010832176

argenx raises approximately $100 million gross proceeds with NASDAQ IPO

 

Regulated information - inside information

Breda, the Netherlands / Ghent, Belgium - argenx (Euronext Brussels: ARGX, Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today the pricing of its initial public offering in the United States (the "Offering") with anticipated gross proceeds totalling approximately $100 million from the sale of 5,865,000 American Depository Shares ("ADSs"), at a price to the public of $17.00 per ADS.

All of the ADSs are being offered by argenx and each of the ADSs offered represents the right to receive one ordinary share.

argenx had earlier increased the Offering from 3.6 million ADSs to 5.0 million ADSs and has finally further increased the Offering to approximately 5.9 million ADSs.

argenx's ordinary shares are listed on the regulated market of Euronext Brussels. The ADSs are expected to begin trading on the NASDAQ Global Select Market on May 18, 2017 under the symbol "ARGX".  The Offering is expected to close on May 23, 2017, subject to customary closing conditions. argenx has granted the underwriters a 30-day option to purchase up to an additional 879,750 ADSs, representing 15% of the ADSs sold in the Offering, to cover over allotments, if any. This option can be exercised during the 30 day period commencing May 17, 2017.

Cowen and Company and Piper Jaffray & Co. are acting as joint bookrunning managers for the Offering, and JMP Securities and Wedbush PacGrow are acting as co-managers. Kempen & Co is argenx's advisor in connection with the Offering.

This Offering is being made only by means of a prospectus. Copies of the final prospectus for this Offering may be obtained, when available, from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by telephone at (631) 274-2806 or by fax at (631) 254-7140 or from Piper Jaffray & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55403, or by telephone at (800) 747-3924, or by email at prospectus@pjc.com. 

A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission ("SEC") on May 17, 2017.

This press release is for information purposes only and does not constitute, and should not be construed as, an offer to sell or the solicitation of an offer to buy or subscribe to any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale is not permitted or to any person or entity to whom it is unlawful to make such offer, solicitation or sale. Reference is also made to the restrictions set out in "Important information" below. This press release is not for publication or distribution, directly or indirectly, in or into any state or jurisdiction into which doing so would be unlawful or where a prior registration or approval is required for such purpose.

About argenx

argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE Antibody(TM) Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.  

For further information, please contact:

Joke Comijn, Corporate Communications Manager
+32 (0)477 77 29 44
+32 (0)9 310 34 19
info@argenx.com

Beth DelGiacco (US IR)
Stern Investor Relations
+1 212 362 1200
beth@sternir.com

Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements argenx makes concerning the intended results of its strategy, the estimated gross proceeds from the Offering and the anticipated closing of the Offering. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements. argenx undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

Important information

No public offering will be made and no one has taken any action that would, or is intended to, permit a public offering in any country or jurisdiction, other than the United States, where any such action is required, including in the European Economic Area. In the European Economic Area, the transaction to which this press release relates will only be available to, and will be engaged in only with, qualified investors within the meaning of Directive 2003/71/EC (together with any applicable implementing measures in the relevant member state of the European Economic Area and as amended, including by Directive 2010/73/EU, to the extent implemented in the relevant member state).

In addition, in the United Kingdom, the transaction to which this press release relates will only be available to, and will be engaged in only with, investment professionals falling within Article 19(5) of the Financial Services and Markets Act (Financial Promotion) Order 2005, as amended (the "Order"), persons falling within Article 49(2) (a) to (d) of the Order, and other persons to whom this announcement may lawfully be communicated (all such persons together being referred to as "relevant persons"). The securities referred to herein are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.